G1 Therapeutics, Inc. (NASDAQ:GTHX) Q3 2023 Earnings Conference Call November 1, 2023 8:30 AM ET

Company Participants

Will Roberts – Vice President-Communications

Jack Bailey – Chief Executive Officer

Andrew Perry – Chief Commercial Officer

Raj Malik – Chief Medical Officer

John Umstead – Chief Financial Officer

Conference Call Participants

Gil Blum – Needham & Company

Dane Leone – RJF

Anupam Rama – JPMorgan

Troy Langford – TD Cowen

Operator

Good day and thank you for standing by. Welcome to the G1 Therapeutics Third Quarter 2023 Financial Results Call. At this time, all participants are in a listen-only mode. After the speakers’ presentation, there will be a question-and-answer session. [Operator Instructions] Please be advised that today's conference is being recorded.

I would now like to hand the conference over to your first speaker today, Will Roberts, Vice President of Communications. Please go ahead.

Will Roberts

Thank you, Teresa. Good morning, everyone, and welcome to the G1 conference call to discuss our third quarter 2023 financial results and business update. The press release on these financial results was issued this morning and can be found in the News section of our website, g1therapeutics.com. On this morning's call, the team will discuss the business overview on the third quarter of 2023, including an update on our clinical programs and our commercial progress in that period with COSELA, which is approved and commercially available to decrease incidents of chemotherapy-induced myelosuppression in patients – adult patients when administered prior to a platinum/etoposide-containing regimen or topotecan-containing regimen for extensive-stage small cell lung cancer. A Q&A session will follow the prepared comments.

Before we begin, I want to remind you that today's webcast contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements represent management's judgment as of today and may involve risks and uncertainties that could cause actual results to differ materially from those expressed in or implied by these statements. For more information on these risks and uncertainties, please refer to our filings with the Securities and Exchange Commission, which are available from the SEC or on our corporate website.

Any forward-looking statements represent our views as of today, November 1, 2023. Joining me on the call are Jack Bailey, our Chief Executive Officer; Andrew Perry, our Chief Commercial Officer; Raj Malik, our Chief Medical Officer; and John Umstead, our Chief Financial Officer.

With that, I'll turn the call over to Jack.